Can pemigatinib treat urothelial cancer?

Incyte is clinically developing pemigatinib, which is currently in Phase II for the treatment of transitional cell carcinoma (urothelial cell carcinoma). The Phase II drug for transitional cell carcinoma (urothelial cell carcinoma) has an 18% stage transition success rate (PTSR) indicator benchmark for progression to Phase III, according to the study. The studyreport evaluated how drug-specific PTSR and Likelihood of Approval (LoA) scores for pemetinib compared to indication benchmarks.

Pemetinib is formulated as tablets for oral administration and is indicated for adults with certain types of previously treated locally advanced or metastatic cholangiocarcinoma and myeloproliferative disorders with fibroblast growth factor receptor 1 (FGFR1) rearrangements. Pemetinib is a potent and selective FGFR 1–3 inhibitor that is safe and tolerable and has demonstrated pharmacological/clinical activity in cholangiocarcinoma, urothelial cancer, recurrent pilocytic astrocytoma, head and neck cancer, pancreatic cancer, gallbladder cancer, uterine cancer, and non-small cell lung cancer.

The original drug of pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 4.5mg*14 tablets may be around 30,000 yuan, which is expensive. The price of the original pemetinib drug, 13.5mg*14 tablets, per box sold overseas may be around RMB 70,000 (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas. For example, the price of a box of 4.5mg*21 tablets produced by a Laos pharmaceutical factory may be around 3,000 yuan (the price may fluctuate due to the exchange rate). The price is relatively cheap. The pharmaceutical ingredients of the generic drugs are basically the same as those of the original drugs at home and abroad.